Integrative metabolomics and gene expression revealed association of RRM2 expression with aggressive breast cancer and tamoxifen resistance, notably pharmacological or genetic inhibition of RRM2 sensitized tumours to tamoxifen treatment [46]. Here, RRM2 is linked to breast cancer.